GenEdit develops next generation therapeutics for genetic diseases through safe and efficient CRISPR/Cas9 delivery.
GenEdit has raised $24.0M in total funding. The most recent round was Series A. The last funding was announced in January 2024.
GenEdit's investors include National Science Foundation, Sequoia Capital, Eli Lilly, Qiming Venture Partners, DCVC Bio.
GenEdit is headquartered in South San Francisco, United States.
GenEdit develops next generation therapeutics for genetic diseases through safe and efficient CRISPR/Cas9 delivery.
GenEdit is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"GenEdit — Funding & Investors." VCBacked, January 23, 2024, https://www.vcbacked.co/company/genedit. Accessed July 19, 2026.
VCBacked. (2024). GenEdit — Funding & Investors. Retrieved July 19, 2026, from https://www.vcbacked.co/company/genedit
{{cite web |title=GenEdit — Funding & Investors |url=https://www.vcbacked.co/company/genedit |website=VCBacked |access-date=July 19, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated